Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non-small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing Hemodialysis

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · New England Journal of Medicine · 2005 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +15

Cancer in patients on dialysis for end-stage renal disease: an international collaborative study

Patrick Maisonneuve, Lawrence Y. Agodoa, Ryszard Gellert et al. · The Lancet · 1999 · 879 citations

Medicine, Nephrology, Oncology +14

BindingDB Entry 50022536: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

PubMed · 2025 · 844 citations · Full text

Medicine, Oncology, Pharmacology +17

Inhibition of Epidermal Growth Factor Receptor-Associated Tyrosine Phosphorylation in Human Carcinomas with CP-358,774: Dynamics of Receptor Inhibition In Situ and Antitumor Effects in Athymic Mice

Vincent A. Pollack, Douglas M. Savage, Deborah A. Baker et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 433 citations

Medicine, Oncology, Pharmacology +17

Effects of Smoking on the Pharmacokinetics of Erlotinib

Marta Hamilton, Julie Wolf, Jason Rusk et al. · Clinical Cancer Research · 2006 · 311 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +10